Clinical impact of severe acute respiratory syndrome coronavirus-2 infection on IgA nephropathy

Masahiro Okabe; Nobuo Tsuboi; Kotaro Haruhara; Shinya Yokote; Akihiro Shimizu; Takaya Sasaki; Hiroyuki Ueda; Takashi Yokoo

doi:10.1111/nep.14171

Clinical impact of severe acute respiratory syndrome coronavirus-2 infection on IgA nephropathy

Nephrology (Carlton). 2023 Jul;28(7):408-409. doi: 10.1111/nep.14171. Epub 2023 May 10.

Authors

Masahiro Okabe^{1

2}, Nobuo Tsuboi^{1

3}, Kotaro Haruhara^{1

4}, Shinya Yokote^{1

5}, Akihiro Shimizu^{1

4}, Takaya Sasaki^{1

6}, Hiroyuki Ueda^{1

3}, Takashi Yokoo^{1

2

3

4

5}

Affiliations

¹ Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
² Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University Daisan Hospital, Tokyo, Japan.
³ Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University Hospital, Tokyo, Japan.
⁴ Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University Kashiwa Hospital, Kashiwa, Japan.
⁵ Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University Katsushika Medical Center, Tokyo, Japan.
⁶ Department of Nephrology, Kawaguchi Municipal Medical Center, Kawaguchi, Japan.

PMID: 37165745
DOI: 10.1111/nep.14171

No abstract available

Publication types

Letter

MeSH terms

COVID-19*
Glomerulonephritis, IGA*
Humans
Immunoglobulin A
Severe acute respiratory syndrome-related coronavirus*

Substances

Immunoglobulin A